RMTG
Regenerative Medical Technology Group Inc.0.0440
+0.0040+10%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
578.11KP/E (TTM)
-Basic EPS (TTM)
-0.56Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Regenerative Medical Technology Group posted Q3 revenue of $1.2M, up 19.7% y/y yet down q/q (derived), with gross profit sliding to $502K as cost of revenue tripled to 57.5% of sales from marketing push and Cancun expansion. Operating loss hit $446K amid 30% higher opex, while net loss ballooned to $4.4M—far exceeding operating shortfall—due to $3.5M interest expense and $416K debt extinguishment loss from August note extensions. Cash edged to $1.2M despite $745K operating outflow; total debt ~$21.5M with $15.4M accrued interest, many notes in default. Debt servicing remains the core risk.
10-Q
Q2 FY2025 results
Revenue jumped 24% y/y to $983.5k in Q2 ended June 30, 2025, with patient procedures doubling to $436.7k while product supplies held steady; gross margins slipped to 59.6% from 66.4%. Operating loss widened slightly to $250k yet net loss halved to $1.3M, thanks to lower interest expense. Cash climbed to $1.6M on $1.1M new debt, but operating cash burned $541k YTD amid $20.5M notes payable (most in default) and $12.4M accrued interest. Debt overhang looms large.
8-K
Q1 sales up 67%, profit positive
Regenerative Medical Technologies Group crushed Q1 2025 with sales over $1.35M, up 67% from Q1 2024, and notched $134,000 in operating profit. They launched turnkey exclusive memberships for clinic setups with ongoing support, locking members into RMTG supplies; onboarding starts at one per quarter. Sales soared. CEO eyes sustained growth across four lines, with formal guidance coming soon.
10-Q
Q1 FY2025 results
Regenerative Medical Technology Group swung to an operating profit of $135K in Q1 FY2025 ended March 31, 2025, from a $105K loss y/y, while revenue doubled 67% y/y to $1.36M (derived), led by patient procedures up 133% to $593K and product supplies up 76% to $627K; gross margin held steady at 69.2%. Yet net loss narrowed to $760K from $1.96M, as interest expense halved to $894K—still dwarfing operations by 6.6x. Cash grew to $1.2M on $57K operating cash flow. Debt burden weighs heavy. Lenders hold first claim.
10-K
FY2024 results
Regenerative Medical Technology Group crushed FY2024 revenue growth at $4.1M, up 70% y/y, fueled by training, products, equipment, and patient procedures—especially Cancun clinic treatments jumping from $319K to $1.4M. Gross profit soared 68% to $2.8M yet operating expenses ticked up 15%, while interest expense narrowed losses to $5.6M from $9.8M prior year. Cash swelled to $1.2M on $851K operating inflow. Revenue doubled annually, but no Q4 breakdown disclosed. Plans call for 2025 clinic launches in Indonesia, Puerto Rico, Chile, Portugal. Debt defaults loom large.
IPO
Sector
Industry
AURX
Nuo Therapeutics, Inc.
2.00-0.15
BSEM
BioStem Technologies, Inc.
3.84-0.11
CLGN
CollPlant Biotechnologies Ltd.
1.53-0.14
FBLG
FibroBiologics, Inc.
0.24-0.02
HRGN
Harvard Apparatus Regenerative
2.00+0.21
MDXG
MiMedx Group, Inc
7.25+0.13
MGRM
Monogram Technologies Inc.
6.00+0.00
NSTM
NovelStem International Corp.
0.02+0.00
RGBP
Regen Biopharma, Inc.
0.01-0.00
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00